GHRH Analogues vs GHRPs: Two Ways to Stimulate Growth Hormone Release
A map of GHRH analogues and ghrelin-receptor secretagogues showing where CJC-1295, sermorelin, ipamorelin and GHRP-6 fit.
Executive Summary
Two peptide families frequently discussed in GH-axis research are GHRH analogues and growth-hormone-releasing peptides. Understanding their upstream receptors prevents misleading comparisons and keeps mechanism separate from clinical benefit.
GHRH Analogues
Sermorelin and CJC-1295 are discussed as GHRH analogues. They act at the GHRH receptor, but structural modifications can change stability and exposure. The label “CJC-1295” is also used inconsistently, so the exact molecular identity and source document matter.
GHRPs and Ghrelin-Receptor Agonists
GHRP-6 and ipamorelin activate the ghrelin receptor. Their pharmacology is not identical, and selectivity or appetite claims should be traced to their supporting evidence. A common receptor does not guarantee a common safety profile.
Interaction Is a Hypothesis
GHRH-receptor and ghrelin-receptor signals can interact at the pituitary. This explains why combinations appear in mechanistic discussions. Biological plausibility does not establish an effective or safe regimen; combination-specific human evidence is required.
Four Evidence Questions
- Does the intervention change GH or IGF-1 biomarkers?
- Does it improve body composition or function?
- Does it improve a defined disease outcome?
- Is the exact product approved for that indication?
One “yes” does not imply the others. Reviews should identify population, endpoint, duration and comparator.
Key Insight
CJC-1295 and sermorelin map mainly to GHRH signaling; ipamorelin and GHRP-6 map to ghrelin-receptor signaling. This map explains mechanism, not proven clinical benefit.